All Stories

  1. An integrated approach to inherited platelet disorders: results from a research collaborative, the Sydney Platelet Group
  2. The effect of metoprolol and aspirin on cardiovascular risk in bereavement: A randomized controlled trial
  3. Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC
  4. The clinical heterogeneity of RUNX1 associated familial platelet disorder with predisposition to myeloid malignancy – A case series and review of the literature
  5. Diagnosis and management of heparin‐induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New ZealandHITWriting Group
  6. Delayed-onset heparin-induced thrombocytopenia complicated by arterial and venous thromboses
  7. N -methyl-d -aspartate receptor mediated calcium influx supports in vitro differentiation of normal mouse megakaryocytes but proliferation of leukemic cell lines
  8. Receptor homodimerization plays a critical role in a novel dominant negative P2RY12 variant identified in a family with severe bleeding
  9. Mean platelet diameter measurements to classify inherited thrombocytopenias
  10. Diagnosis and treatment of MYH9-RD in an Australasian cohort with thrombocytopenia
  11. Thrombocytopenia and CD34 expression is decoupled from α-granule deficiency with mutation of the first growth factor-independent 1B zinc finger
  12. Anti-glycoprotein VI mediated immune thrombocytopenia: An under-recognized and significant entity?
  13. GFI1B variants associated with thrombocytopenia
  14. The impact of frailty on coagulation and responses to warfarin in acute older hospitalised patients with atrial fibrillation: a pilot study
  15. Inhibition of NMDA receptor function with an anti-GluN1-S2 antibody impairs human platelet function and thrombosis
  16. Heparin-induced multi-electrode aggregometry method for heparin-induced thrombocytopenia testing: communication from the SSC of the ISTH
  17. Effect of Frailty and Age on Platelet Aggregation and Response to Aspirin in Older Patients with Atrial Fibrillation: A Pilot Study
  18. Differentiation between dogs with thrombosis and normal dogs using the overall hemostasis potential assay
  19. Inhibition of glutamate regulated calcium entry into leukemic megakaryoblasts reduces cell proliferation and supports differentiation
  20. Paris-Trousseau thrombocytopenia is phenocopied by the autosomal recessive inheritance of a DNA-binding domain mutation in FLI1
  21. Low levels of CD9 coincidental with a novel nonsense mutation in glycoprotein Ibβ in a patient with Bernard-Soulier syndrome
  22. Role of Nongenomic Signaling Pathways Activated by Aldosterone During Cardiac Reperfusion Injury
  23. The Effect of Omega-3 Polyunsaturated Fatty Acids on Fibrin and Thrombin Generation in Healthy Subjects and Subjects with Cardiovascular Disease
  24. Inherited Macrothrombocytopenias
  25. Platelets are not all gray in GFI1B disease
  26. Spectrum of the Mutations in Bernard-Soulier Syndrome
  27. N-methyl-d-aspartate receptors amplify activation and aggregation of human platelets
  28. Evaluation and modification of the overall hemostasis potential assay for use with canine plasma
  29. GFI1Bmutation causes a bleeding disorder with abnormal platelet function
  30. Using HitAlert flow cytometry to detect heparin-induced thrombocytopenia antibodies in a tertiary care hospital
  31. Detection of hypofibrinolysis in stable coronary artery disease using the overall haemostatic potential assay
  32. Effects of Omega-3 Polyunsaturated Fatty Acids on Platelet Function in Healthy Subjects and Subjects with Cardiovascular Disease
  33. Effect of Early Bereavement on Heart Rate and Heart Rate Variability
  34. Reduced T helper and B lymphocytes in Parkinson's disease
  35. Diurnal changes and levels of fibrin generation are not altered by continuous positive airway pressure (CPAP) in obstructive sleep apnoea (OSA)
  36. Platelets and innate inflammation in pregnancy
  37. Effects of continuous positive airway pressure on coagulability in obstructive sleep apnoea: a randomised, placebo-controlled crossover study
  38. Evaluating Heparin-Induced Thrombocytopenia: The Old and the New
  39. Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT
  40. Severe FX deficiency caused by a previously unidentified 4-bp deletion compound heterozygous with a large deletion involving FVII and FX genes
  41. Inflammatory and thrombotic changes in early bereavement: a prospective evaluation
  42. False negative or false positive: laboratory diagnosis of lupus anticoagulant at the time of commencement of anticoagulant: reply to a rebuttal
  43. Haemodynamic Changes During Early Bereavement: Potential Contribution to Increased Cardiovascular Risk
  44. Heparin-induced thrombocytopenia: evaluation of IgG and IgGAM ELISA assays
  45. False-negative or false-positive: laboratory diagnosis of lupus anticoagulant at the time of commencement of anticoagulant
  46. Effect of Omega-3 Fish Oil on Cardiovascular Risk in Diabetes
  47. Whole blood impedance aggregometry detects heparin-induced thrombocytopenia antibodies
  48. Prospective study of early bereavement on psychological and behavioural cardiac risk factors
  49. The association of depression with platelet activation: evidence for a treatment effect
  50. Mesenchymal Stem Cells: Isolation, Characterisation and In Vivo Fluorescent Dye Tracking
  51. Use of a functional assay to diagnose protein S deficiency; inappropriate testing yields equivocal results
  52. Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall hemostatic potential assay
  53. Heterozygous loss of platelet glycoprotein (GP) Ib-V-IX variably affects platelet function in velocardiofacial syndrome (VCFS) patients
  54. Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels?
  55. A common ancestral glycoprotein (GP) 9 1828A>G (Asn45Ser) gene mutation occurring in European families from Australia and Northern Europe with Bernard-Soulier syndrome (BSS)
  56. An immediate hemolytic reaction induced by repeated administration of oxaliplatin
  57. Eleven human platelet systems studied in the Vietnamese and Ma'ohis Polynesian populations
  58. Green fluorescent protein (GFP) tagged to the cytoplasmic tail of αIIb or β3 allows the expression of a fully functional integrin αIIbβ3: effect of β3GFP on αIIbβ3 ligand binding
  59. Lack of platelet response to collagen associated with autoantibodies against glycoprotein (GP) Ia/IIa and Ib/IX leading to the discovery of SLE
  60. Antiplatelet antibodies during the course of HIV-preventive vaccine trial
  61. Genetic susceptibility and anti-human platelet antigen 5b alloimmunization role of HLA class II and TAP genes
  62. Drawbacks of the MAIPA technique in characterising human antiplatelet antibodies
  63. The molecular genetic basis of Glanzmann's thrombasthenia in a gypsy population in France: identification of a new mutation on the alpha IIb gene
  64. Platelet phenotyping in carriers for Glanzmann's thrombasthenia: a simple screening test for assessment of the molecular defect
  65. Heparin- and Streptokinase-Dependent Platelet-Activating Immunoglobulin G: Mechanism and Diagnosis
  66. Maternal Thrombocytopenia During Pregnancy: Diagnosis and Etiology
  67. Human platelet alloantigen typing: PCR analysis is not a substitute for serological methods
  68. MHC class II region including TAP genes controls the genetic susceptibility to anti-Gp IB IX autoimmune thrombocytopenia
  69. Neonatal thrombocytopenia and hidden maternal autoimmunity
  70. Studies on the HLA Class-II Antigens of a Patient Presenting a Double Alloimmunization Following Posttransfusion Purpura
  71. Anti-HPA-4b (anti-Yuka) neonatal alloimmune thrombocytopenia: first report in a Caucasian family
  72. Fetal and neonatal alloimmune thrombocytopenia: current trends in diagnosis and therapy
  73. Polymorphisme des groupes plaquettaires en Provence. Comparaison avec les fréquences des allo-antigènes spécifiques plaquettaires observées dans les autres populations
  74. HPA-5b (Bra) neonatal alloimmune thrombocytopenia: clinical and immunological analysis of 39 cases
  75. AIDS vaccine therapy: phase I trial
  76. Aeguorin-detected calcium changes in stimulated thrombasthenic platelets. Aggregation - dependent calcium movement in response to ADP
  77. Decreased stability and structural heterogeneity of the residual platelet glycoprotein IIb/IIIa complex in a variant of Glanzmann's thrombasthenia
  78. Calcium rise in human platelets elicited by anti-CD9 and -CD41 murine monoclonal antibodies
  79. PL2-49, a monoclonal antibody against glycoprotein IIb which is a platelet activator